• PureTech ESG report outlined a shift toward earlier formation of externally funded Founded Entities to cut operating burn at parent level.
• Year-end PureTech level cash, cash equivalents, short-term investments fell to USD 277.1 million from USD 366.8 million in 2024.
• Board decided to concentrate trading on London Stock Exchange, plan voluntary delisting of American Depositary Shares from Nasdaq.
• CEO strategy set goal to return a higher proportion of future cash generation to shareholders, with focus on “outsized” portfolio returns.
• Portfolio update flagged Celea deupirfenidone as Phase 3-ready, with financing targeted to close early Q3 2026 to start SURPASS-IPF trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PureTech Health plc published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.